YOUR GUIDE TO THE TWIN CITIES









AVEO Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. AVEO has advanced its lead product, tivozanib (AV-951), a triple VEGF receptor inhibitor, through a recently completed Phase 2 clinical trial in patients with metastatic renal cell cancer (mRCC), and expects to enter Phase 3 development in 2009.
The Company hosts a monthly luncheon for its employees. We use the forum to introduce new employees and update the company on any recent events. We celebrate our employees’ birthdays each month with a personalized birthday card and a cake. During the summer we sponsor an Ice Cream Truck to provide a mid-day treat for our employees. The President and CEO of the Company is the recipient of the 2007 Ernst & Young New England Entrepreneur of the Year.
ADVERTISEMENT
425 Portland Av. S.
Minneapolis, MN 55488
(612) 673-4000
© 2011 StarTribune. All rights reserved.
StarTribune.com is powered by Clickability